N Lynn Henry Selected Research

Aromatase Inhibitors

10/2022	Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
12/2021	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
1/2021	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
1/2021	Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
1/2021	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
1/2021	Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
1/2020	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
11/2019	Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
1/2019	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
12/2018	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

N Lynn Henry Research Topics

Disease

90	Breast Neoplasms (Breast Cancer) 10/2022 - 01/2006
28	Neoplasms (Cancer) 01/2022 - 01/2006
14	Pain (Aches) 10/2022 - 09/2008
9	Peripheral Nervous System Diseases (PNS Diseases) 08/2022 - 01/2018
6	Arthralgia (Joint Pain) 12/2021 - 09/2010
3	Circulating Neoplastic Cells 01/2022 - 06/2015
3	Hot Flashes 12/2021 - 07/2009
3	Chronic Pain 01/2018 - 12/2011
2	Noninfiltrating Intraductal Carcinoma (DCIS) 12/2021 - 11/2021
2	Neoplasm Metastasis (Metastasis) 02/2021 - 08/2012
2	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 11/2019
2	Disease Progression 12/2019 - 01/2006
2	Fatigue 01/2018 - 08/2014
2	Syndrome (Syndromes) 01/2016 - 08/2014
2	Hypertension (High Blood Pressure) 01/2016 - 07/2015
2	Musculoskeletal Pain 08/2014 - 05/2011
1	Frailty 01/2022
1	Alopecia (Baldness) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Microsatellite Instability 01/2022
1	Dihydropyrimidine Dehydrogenase Deficiency 01/2022
1	Thrombosis (Thrombus) 12/2021
1	Osteoarthritis 12/2021
1	Osteonecrosis (Kienbock's Disease) 02/2021
1	Pathologic Complete Response 12/2020
1	Uterine Neoplasms (Uterine Cancer) 11/2020
1	Exanthema (Rash) 07/2020
1	Lung Neoplasms (Lung Cancer) 07/2020
1	Vitamin D Deficiency 04/2020
1	Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy) 01/2020
1	Obesity 01/2019
1	Drug-Related Side Effects and Adverse Reactions 10/2018

Drug/Important Bio-Agent (IBA)

32	Aromatase InhibitorsIBA 10/2022 - 09/2008
29	Hormones (Hormone)IBA 10/2022 - 01/2006
16	Letrozole (Femara)FDA LinkGeneric 10/2022 - 09/2008
15	exemestane (Aromasin)FDA Link 10/2022 - 09/2008
13	Estrogen ReceptorsIBA 01/2022 - 01/2012
11	Paclitaxel (Taxol)FDA LinkGeneric 08/2022 - 01/2018
9	Biomarkers (Surrogate Marker)IBA 08/2022 - 11/2011
6	Tamoxifen FDA LinkGeneric 12/2021 - 10/2009
6	Pharmaceutical PreparationsIBA 12/2021 - 07/2009
6	Estrogens (Estrogen)FDA Link 01/2019 - 05/2014
5	human ERBB2 proteinIBA 01/2022 - 06/2015
4	Anastrozole (Arimidex)FDA LinkGeneric 12/2021 - 04/2017
4	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2021 - 12/2011
3	AnthracyclinesIBA 01/2022 - 07/2015
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2015
3	ParaffinIBA 01/2019 - 11/2015
3	Formaldehyde (Formol)FDA Link 01/2019 - 11/2015
3	ametantrone (HAQ)IBA 07/2017 - 09/2008
3	Tumor Biomarkers (Tumor Markers)IBA 01/2015 - 06/2006
3	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2012 - 10/2009
2	taxaneIBA 10/2022 - 01/2018
2	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2016
2	Biological ProductsIBA 01/2022 - 12/2019
2	Trastuzumab (Herceptin)FDA Link 12/2020 - 08/2012
2	ErbB Receptors (EGF Receptor)IBA 07/2020 - 10/2014
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2019 - 12/2011
2	Serotonin (5 Hydroxytryptamine)IBA 01/2019 - 12/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2016 - 07/2015
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2016 - 01/2016
1	dostarlimabIBA 01/2022
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2022
1	pembrolizumabIBA 01/2022
1	AlpelisibIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Azacitidine (5 Azacytidine)FDA Link 01/2022
1	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2022
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022
1	Fluorouracil (Carac)FDA LinkGeneric 11/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2021
1	Capecitabine (Xeloda)FDA Link 11/2021
1	Zoledronic Acid (Zometa)FDA Link 02/2021
1	Lapatinib (GW572016)FDA Link 12/2020
1	Vitamin D FDA LinkGeneric 04/2020
1	Folic Acid (Vitamin M)FDA LinkGeneric 04/2020
1	HomocysteineIBA 04/2020
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 04/2020
1	ORALIT (ORS)IBA 11/2019
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 12/2018
1	Phenylalanine (L-Phenylalanine)FDA Link 10/2018
1	Histidine (L-Histidine)FDA Link 10/2018
1	Aligeron (AS 2)IBA 10/2018
1	salicylhydroxamic acid (SHAM)IBA 10/2018
1	Threonine (L-Threonine)FDA Link 10/2018

Therapy/Procedure

48	Therapeutics 01/2022 - 01/2006
20	Drug Therapy (Chemotherapy) 08/2022 - 11/2006
6	Adjuvant Chemotherapy 01/2017 - 01/2006
3	Radiotherapy 11/2021 - 07/2015
2	Aftercare (After-Treatment) 01/2019 - 12/2011
1	Time-to-Treatment 10/2022
1	Immunotherapy 01/2022
1	Complementary Therapies (Alternative Medicine) 10/2021
1	Integrative Oncology 10/2021
1	Mastectomy (Mammectomy) 05/2021
1	Dental Care 02/2021
1	Neoadjuvant Therapy 12/2020
1	Salpingo-oophorectomy 11/2019